Suppr超能文献

TLI 在儿科患者中的应用。

TLI in pediatric patients.

机构信息

Radiation Oncology Department, Hospital Universitario La Paz, Pº de La Castellana, 261, Madrid, 28046, Spain.

Radiophysics and Radioprotection Department, Hospital Universitario La Paz, Pº de La Castellana, 261, Madrid, 28046, Spain.

出版信息

Clin Transl Oncol. 2020 Jun;22(6):884-891. doi: 10.1007/s12094-019-02205-9. Epub 2019 Sep 21.

Abstract

PURPOSE

Hematopoietic progenitor cell transplantation (HSCT) is a procedure used in different hematological diseases as part of the curative treatment, so the investigators propose a system of conditioning of reduced intensity based on total lymphoid irradiation (TLI) as an alternative to the classic total body irradiation (TBI) followed by haploidentical transplantation in patients compatible with a single HLA haplotype, as an alternative to patients who do not have an HLA compatible donor.

MATERIALS AND METHODS

A cohort of 25 patients with hematological disease underwent haploidentical HSCT from February 2015 to May 2018, conditioned with TLI from day - 10 (2-4 days of treatment) followed by thiotepa (5 mg/kg/12 h) and melphalan (70 mg/m/day) prior to HSCT and prophylaxis with ciclosporin (1.5 mg/kg/12 h). 2 Gy/fraction was administered to complete 8 Gy with IMRT and VMAT technique.

RESULTS

12% rejection of the transplant was obtained with acute GVHD < II (48%) and chronic GVHD 12%. No acute toxicity was recorded in irradiated patients and 56% survival of patients at the end of follow-up.

CONCLUSION

Conditioning the haploidentical transplant with TLI, IMRT, and VMAT techniques compared with TBI and RT3D-C techniques is a feasible technique that helps inducing the necessary immunosuppression in patients with a high risk of graft rejection, minimal adverse effects, low incidence of GVHD, and high survival rate.

摘要

目的

造血祖细胞移植(HSCT)是一种用于不同血液疾病的治疗方法,作为治愈治疗的一部分,因此研究人员提出了一种基于全身淋巴照射(TLI)的低强度预处理方案,作为经典全身照射(TBI)的替代方案,用于与单个 HLA 单倍型相容的患者进行半相合移植,作为替代不具有 HLA 相容供体的患者的替代方案。

材料和方法

一组 25 名患有血液疾病的患者于 2015 年 2 月至 2018 年 5 月接受了半相合 HSCT,在 HSCT 前用 TLI 预处理,从第-10 天开始(2-4 天治疗),随后用噻替哌(5mg/kg/12h)和马法兰(70mg/m/天),并进行环孢素(1.5mg/kg/12h)预防。采用 IMRT 和 VMAT 技术给予 2Gy/ 分次,以完成 8Gy 的照射。

结果

25 名患者中有 3 名(12%)发生急性移植物抗宿主病 < II 级(48%)和慢性移植物抗宿主病 12%。在接受照射的患者中未记录到急性毒性,随访结束时患者的存活率为 56%。

结论

与 TBI 和 RT3D-C 技术相比,用 TLI、IMRT 和 VMAT 技术对半相合移植进行预处理是一种可行的技术,可帮助高排斥风险患者诱导必要的免疫抑制,不良反应最小,GVHD 发生率低,生存率高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验